hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06339320, orgStudyIdInfo id: PRO00037835, briefTitle: Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2033-10, completionDateStruct date: 2033-10, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: The Methodist Hospital Research Institute, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate endoscopic sleeve gastroplasty (ESG) for the treatment of obesity. The ESG procedure is an U.S. Food and Drug Administration (FDA) approved procedure for the treatment of obesity - patients with a body mass index (BMI) 30-50 kg/m2. This procedure is FDA approved; however, Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-Accredited centers (such as Houston Methodist Hospital) must receive approval from an Institutional Review Board (IRB) in order to perform primary procedures, such as ESG, that are not endorsed by the American Society for Metabolic and Bariatric Surgery (ASMBS)., conditionsModule conditions: Endoscopic Sleeve Gastroplasty, conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Retrospective Registry Study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Endoscopic Sleeve Gastroplasty (ESG), interventions name: Apollo OverStitch endoscopic suturing device, outcomesModule primaryOutcomes measure: Number of participants with technically successful completion of the ESG procedure, primaryOutcomes measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, secondaryOutcomes measure: Change in body mass index (BMI) measured by kg/m2, secondaryOutcomes measure: Change in hemoglobin A1C (%), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Houston Methodist Hospital, status: RECRUITING, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Thomas R McCarty, MD, MPH, role: CONTACT, phone: 713-363-7436, email: tommccarty3@houstonmethodist.org, geoPoint lat: 29.76328, lon: -95.36327, locations facility: Houston Methodist Hospital - Sugarland, status: RECRUITING, city: Sugar Land, state: Texas, zip: 77479, country: United States, contacts name: Thomas R McCarty, MD, MPH, role: CONTACT, phone: 713-363-7436, email: tommccarty3@houstonmethodist.org, geoPoint lat: 29.61968, lon: -95.63495, hasResults: False
protocolSection identificationModule nctId: NCT06339307, orgStudyIdInfo id: DJY004, briefTitle: A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Tianjin Medical University Cancer Institute and Hospital, class: OTHER, descriptionModule briefSummary: In our prior research, a risk scoring model for the occurrence of lymph node metastasis in patients who underwent radical gastrectomy for gastric cancer was established. To further validate this scoring model, a prospective study has been designed with the aim of prospectively assessing the model's clinical applicability., conditionsModule conditions: Predictive Cancer Model, conditions: Gastric Cancer, conditions: Lymph Node Metastasis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: lymph node metastasis, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer Hospital of Tianjin Medical University, status: RECRUITING, city: Tianjin, state: Tianjin, country: China, contacts name: Jingyu Deng, M.D., role: CONTACT, phone: +86-22-23340123, email: dengery@126.com, geoPoint lat: 39.14222, lon: 117.17667, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2023-07-01, uploadDate: 2024-03-17T10:10, filename: Prot_000.pdf, size: 131262, largeDocs typeAbbrev: SAP, hasProtocol: False, hasSap: True, hasIcf: False, label: Statistical Analysis Plan, date: 2023-07-01, uploadDate: 2024-03-17T10:11, filename: SAP_001.pdf, size: 158196, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2023-07-01, uploadDate: 2024-03-17T10:11, filename: ICF_002.pdf, size: 151390, hasResults: False
protocolSection identificationModule nctId: NCT06339294, orgStudyIdInfo id: ZShabbir, briefTitle: Efficacy of Pyodine Soaked Gelfoam vs Single Topical Application of Clotrimazole in Otomycosis Treatment, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-16, primaryCompletionDateStruct date: 2023-12-15, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Rawalpindi Medical College, class: OTHER, descriptionModule briefSummary: Background and Objectives To compare the efficacy of gel foam-soaked pyodine with a single topical application of clotrimazole ointment.Subjects and Methods This randomized controlled trial will include 90 patients presenting to ENT OPD with complaints of earache, watery ear discharge, pruritis, and ear blockage and will be clinically diagnosed as a case of otomycosis on otoscopy. The external auditory canal of the patient will be cleared of fungal debris via suction before treatment In Group A ear canal will be filled with 1% clotrimazole ointment by using an IV catheter and syringe and in Group B pyodine-soaked gel foam will be placed in the external auditory canal. The patients will be followed up on post-treatment days 7 and 14., conditionsModule conditions: Otomycosis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 90, type: ACTUAL, armsInterventionsModule interventions name: Clotrimazole Cream, interventions name: Povidone-Iodine, outcomesModule primaryOutcomes measure: Treatment Response Based on Otoscopy, secondaryOutcomes measure: Condition of External Auditory Canal, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Benazir Bhutto Hospital, city: Rawalpindi, state: Punjab/46000, zip: 46000, country: Pakistan, geoPoint lat: 33.6007, lon: 73.0679, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-05-16, uploadDate: 2024-03-24T05:10, filename: Prot_SAP_000.pdf, size: 557916, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2023-06-16, uploadDate: 2024-03-24T05:13, filename: ICF_001.pdf, size: 1206939, hasResults: False
protocolSection identificationModule nctId: NCT06339281, orgStudyIdInfo id: 2023YJZ87, briefTitle: A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Li Huiping, class: OTHER, descriptionModule briefSummary: Previous studies have found good efficacy of (investigator's choice of chemotherapy, or endocrine drug) in combination with apatinib mesylate in the treatment of her-2 negative, chest wall metastatic advanced breast cancer, and the present study proposes to further explore the efficacy of apatinib mesylate in her-2 negative, HR-positive advanced breast cancer., conditionsModule conditions: Advanced Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: apatinib mesylate+Capecitabine Tablets, interventions name: apatinib mesylate+Fulvestrant injection, outcomesModule primaryOutcomes measure: Progression-free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06339242, orgStudyIdInfo id: 2024-01-NSCLC, briefTitle: A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2026-01-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Jiangsu Province Nanjing Brain Hospital, class: OTHER, descriptionModule briefSummary: Leptomeningeal metastasis is a fatal complication of advanced lung cancer. There is no standard treatment for leptomeningeal metastasis after third-generation EGFR-TKIs. The Furmonertinib prototype persists longer in brain tissue, and its metabolites can also penetrate the blood-brain barrier. Ommaya cystlateral ventricle chemotherapy can quickly control the progression of intracranial lesions. The aim of this study is to evaluate the LM progression-free survival (LM-PFS) of Furmonertinib combined with lateral ventricular chemotherapy in the treatment of leptomeningeal metastatic NSCLC after third-generation EGFR-TKIs resistance., conditionsModule conditions: NSCLC, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Furmonertinib, outcomesModule primaryOutcomes measure: LM-PFS（progression-free survival）, primaryOutcomes measure: LM-ORR（Objective response rate）, secondaryOutcomes measure: LM-OS, secondaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events, secondaryOutcomes measure: PFS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nanjing Brain Hospital, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210029, country: China, contacts name: fang S Cun, role: CONTACT, phone: 83728558, phoneExt: 025, email: fang1984@aliyun.com, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06339229, orgStudyIdInfo id: FSYYY-2024-12, briefTitle: Postoperative New-onset Proteinuria and Adverse Outcomes., statusModule overallStatus: COMPLETED, startDateStruct date: 2000-01-01, primaryCompletionDateStruct date: 2022-12-31, completionDateStruct date: 2023-11-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Yaozhong Kong, class: OTHER, descriptionModule briefSummary: We aimed to assess the association between postoperative new-onset proteinuria, all-cause mortality, and decline in kidney function in Chinese people who underwent surgery. The exposure variable was the dipstick proteinuria values from the initial postoperative urinalysis within 30 days after surgery, categorized as negative, trace, 1+, and ≥2+. The primary outcome was 30-day mortality. The secondary outcomes included 1-year mortality and composite kidney outcome assessed using the postoperative estimated glomerular filtration rate., conditionsModule conditions: Surgery, conditions: Proteinuria, conditions: Mortality, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 2983899, type: ACTUAL, armsInterventionsModule interventions name: proteinuria, outcomesModule primaryOutcomes measure: mortality, eligibilityModule sex: ALL, minimumAge: 16 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06339216, orgStudyIdInfo id: OBU-BJ-GC-II-011, briefTitle: A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2026-11-30, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Chinese PLA General Hospital, class: OTHER, descriptionModule briefSummary: Phase II Clinical Study of Adebrelimab Combined with Apatinib and Paclitaxel for Injection(Albumin Bound) as Second-line Therapy in Patients with Advanced Gastric Cancer Previously Treated with Immunotherapy, conditionsModule conditions: Gastric Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound), outcomesModule primaryOutcomes measure: ORR, secondaryOutcomes measure: PFS, secondaryOutcomes measure: DCR, secondaryOutcomes measure: OS, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06339203, orgStudyIdInfo id: 5240002, briefTitle: Intraoperative Wound Irrigation in Cesarean Section, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Loma Linda University, class: OTHER, collaborators name: Irrimax Corporation, descriptionModule briefSummary: This investigator-initiated, open-label, randomized controlled trial will explore the effects of two treatment arms, comparing standard treatment with normal saline against Irrisept, a jet lavage solution containing a low concentration of Chlorhexidine Gluconate (CHG) at 0.05% in 99.95% sterile water for irrigation. The study aims to evaluate the impact on postoperative wound healing in patients who have undergone cesarean delivery., conditionsModule conditions: Cesarean Section Complications, conditions: Cesarean Section; Infection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Irrisept, interventions name: Normal Saline, outcomesModule primaryOutcomes measure: Composite wound evaluation after caesarean delivery, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Loma Linda University, city: Loma Linda, state: California, zip: 92354, country: United States, contacts name: Nikia Gray Hutto, AS, role: CONTACT, phone: 909-558-4000, phoneExt: 44428, email: nhutto@llu.edu, geoPoint lat: 34.04835, lon: -117.26115, hasResults: False
protocolSection identificationModule nctId: NCT06339190, orgStudyIdInfo id: E21-006-72840, briefTitle: Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis, acronym: NAVAIDD, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-08-01, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2027-12, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Monash University, class: OTHER, collaborators name: Eastern Health, collaborators name: University of Melbourne, collaborators name: Wake Forest University, collaborators name: Deakin University, collaborators name: The Florey Institute of Neuroscience and Mental Health, collaborators name: Invitae Corporation, collaborators name: Redenlab, descriptionModule briefSummary: This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests.Participants will have a single blood test and speech test, and will be followed up at 12-months to complete questionnaires and cognitive scales over the phone. The speech test will also be completed again at 12-months.Individuals at risk of a Fronto-temporal dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample., conditionsModule conditions: Neurodegenerative Diseases, conditions: Dementia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Venepuncture, outcomesModule primaryOutcomes measure: Nfl correlation with neurodegeneration, secondaryOutcomes measure: Change in speech processing, secondaryOutcomes measure: Change in language processing, secondaryOutcomes measure: Change in Direct Magnitude Estimation, otherOutcomes measure: Modified Rankin Scale, otherOutcomes measure: Montreal Cognitive Assessment score, otherOutcomes measure: Hospital Anxiety and Depression Scale score, otherOutcomes measure: Clinical Global Impression score, otherOutcomes measure: WHO Disability Assessment 12-item telephone interview score, otherOutcomes measure: WHO Disability Assessment 36-item self report score, otherOutcomes measure: DNA sample for testing known pathogenic dementia mutations, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Box Hill Hospital, status: RECRUITING, city: Box Hill, state: Victoria, zip: 3128, country: Australia, contacts name: Svetlana Ivanic, role: CONTACT, email: svetlana.ivanic@monash.edu, geoPoint lat: -37.81887, lon: 145.12545, locations facility: Wantirna Health, status: RECRUITING, city: Wantirna, state: Victoria, zip: 3152, country: Australia, contacts name: Sarah Shue, role: CONTACT, geoPoint lat: -37.85, lon: 145.21667, hasResults: False
protocolSection identificationModule nctId: NCT06339164, orgStudyIdInfo id: ObGynEASC006, briefTitle: Breech Delivery Skills. Resident Learning Program, acronym: Breech, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-05-15, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: G. d'Annunzio University, class: OTHER, descriptionModule briefSummary: Breech delivery is one of the mail topic in emergency obstetrics for Italian Board of Obstetrics and Gynecology. Formal frontal lecture and digital learning represent nowadays the two typical learning methods. A bedside evaluation it's not feasible due to rarity of such emergency, due to the common senior physicians involvement when it occurs, and due to medico-legal risks. Mannequin scenario represents the best way of skill evaluation, conditionsModule conditions: Breech Presentation; Before Labor, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: skills and learning quality in breech delivery, outcomesModule primaryOutcomes measure: Skills capacities, primaryOutcomes measure: Skills capacities, secondaryOutcomes measure: learning qualities, eligibilityModule sex: ALL, minimumAge: 24 Years, maximumAge: 38 Years, stdAges: ADULT, contactsLocationsModule locations facility: Claudio Celentano, city: Pescara, state: PE, zip: 65100, country: Italy, geoPoint lat: 42.4584, lon: 14.20283, hasResults: False
protocolSection identificationModule nctId: NCT06339151, orgStudyIdInfo id: TUH multiple dexamethasone TKA, briefTitle: Comparing Single Dose and Multiple Dose of Dexamethasone Post TKA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-23, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2025-10-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Thammasat University Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to investigate the efficacy of single dose and double dose of dexamethasone after primary total knee replacement.The main question\[s\] it aims to answer \[is/are\]:Does 24 hours-interval of double dose of dexamethasone have better analgesic effect than single dose and 12 hours interval of double dose of dexamethasone after primary total joint replacement?Researchers will compare double dose of dexamethasone group to see if \[insert effects\].Participants will \[describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items\]., conditionsModule conditions: Osteo Arthritis Knee, conditions: Pain, Postoperative, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Dexamethasone before surgery, interventions name: Dexamethasone before and 12 hours after surgery, interventions name: Dexamethasone before and 24 hours after surgery, outcomesModule primaryOutcomes measure: Pain at rest and motion, secondaryOutcomes measure: Nausea and vomiting, secondaryOutcomes measure: Morphine consumption, secondaryOutcomes measure: Blood sugar level, secondaryOutcomes measure: CRP level, secondaryOutcomes measure: Range of motion, secondaryOutcomes measure: Length of hospital stay, secondaryOutcomes measure: Complication, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Thammasat University Hospital, status: RECRUITING, city: Khlong Luang, state: Pathum Thani, zip: 12120, country: Thailand, contacts name: Yot Tanariyakul, M.D., role: CONTACT, phone: 6683930257, email: y.tanariyakul@gmail.com, contacts name: Yot Tanariyakul, M.D., role: PRINCIPAL_INVESTIGATOR, contacts name: Piya Pinsornsak, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 14.06467, lon: 100.64578, hasResults: False